Boston Scientific Corp., Natick, Mass., said it is expanding its manufacturing capabilities in Minnesota, one of two locations where the company makes its Taxus drug-eluting stent.
Taxus, also produced in Galway, Ireland, is being sold internationally, and Food and Drug Administration approval is expected this quarter. The stent would be the first competitor to Johnson & Johnson's drug-eluting Cypher stent, which won FDA approval last April.
Boston Scientific said it would construct a new 120,000-square-foot building in Maple Grove, Minn., primarily for research and development laboratories and for office space for up to 600 new employees.
In a related matter, Cordis Corp., the J&J unit that manufactures the Cypher stent, said it has completed enrollment in an international clinical trial directly comparing the performance of the Cypher and Taxus stents, particularly in high-risk patient groups such as diabetics.